4//SEC Filing
Power Sean A 4
Accession 0001104659-22-082024
CIK 0001001316other
Filed
Jul 21, 8:00 PM ET
Accepted
Jul 22, 4:33 PM ET
Size
7.8 KB
Accession
0001104659-22-082024
Insider Transaction Report
Form 4
Power Sean A
CFO
Transactions
- Award
Common Stock
2022-07-20+75,000→ 643,483 total - Award
Employee Stock Option (right to buy)
2022-07-20+200,000→ 200,000 totalExercise: $7.00Exp: 2027-07-20→ Common Stock, par value $0.001 (200,000 underlying)
Footnotes (3)
- [F1]Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab.
- [F2]Includes shares of restricted Common Stock, which vest over various time periods.
- [F3]Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis.
Documents
Issuer
TG THERAPEUTICS, INC.
CIK 0001001316
Entity typeother
Related Parties
1- filerCIK 0001538845
Filing Metadata
- Form type
- 4
- Filed
- Jul 21, 8:00 PM ET
- Accepted
- Jul 22, 4:33 PM ET
- Size
- 7.8 KB